Explore Viatris (VTRS) stock price, latest earnings, technical analysis, analyst ratings, and valuation. Is VTRS stock a buy? Get balanced insights for investors as of March 2026
Introduction
Viatris makes generic drugs and biosimilars. It serves patients worldwide with affordable medicines. Investors watch VTRS stock now due to strong Q4 results. Broader pharma sector faces patent cliffs but gains from demand for low-cost drugs.
VTRS stock price rose after beating earnings estimates. Market conditions favor generics amid rising healthcare costs.
Latest Stock Price & Trend
VTRS stock closed at $16.08 on February 25, 2026, the last trading day before Q4 data. It ranged from $15.14 to $16.47 that day. The 52-week high hit $16.47, while the low was $6.85.
Year-to-date, VTRS stock shows gains near its peak. Over three months, it climbed about 21%, and one month saw 14% rise. Six-month and one-year trends point up from lows, though YTD was flat earlier.
The overall trend looks bullish. It signals growing investor confidence post-earnings. Everyday investors may see entry points near supports.
Technical Analysis
Support levels are prices where buyers step in, like $15.14 recent low. Resistance is at $16.47, the 52-week high where sellers may emerge.
RSI measures speed of price moves. A reading near 60 suggests neutral, not overbought or oversold. MACD tracks momentum; if above signal line, it’s bullish for VTRS now.
The 50-day moving average smooths short-term trends. The 200-day covers longer views; VTRS trades above both, showing strength. No recent golden cross (50-day over 200-day) but upward bias. Volume spiked on earnings, confirming interest.
Analyst Ratings & Price Targets
Seven analysts rate VTRS: 3 sell, 2 hold, 2 buy. Average price target is $11.17, with high $14 and low $8. Eight analysts average $12.38, high $15 from Argus.
Recent views mix caution with upside. Barclays low at $9; Argus optimistic. Sentiment leans hold; targets below current price suggest fair value.
This means analysts see limited near-term gains. Investors should weigh against strong earnings beat.
Insider Activity
Insiders bought $535.8K in shares last three months. No major sells noted recently. Positive score from one transaction.
Trends show confidence. Non-open market buys signal management optimism. This implies insiders back the stock’s future.
Valuation Analysis
Trailing P/E is negative at -3.44 due to past losses; forward P/E 6.08 looks cheap. Price-to-sales is 1.25.
Q4 revenue grew to $3.7B, up from $3.53B YoY, beat estimates by 5%. EPS $0.57 beat $0.52 forecast. Free cash flow supports dividends at 4.5% yield.
Debt position stable in generics peers like Teva. VTRS appears undervalued vs. forward growth.
Recent Earnings & Catalysts
Q4 2025 EPS hit $0.57 vs. $0.52 expected, surprise +9.6%. Revenue $3.7B topped forecasts. Beat prior year $0.54 EPS.
Guidance: Q1 EPS $0.58 on $3.31B revenue; FY $2.50 on $14.34B. Catalysts include biosimilar expansions. Stock jumped post-earnings.
Bullish Case
Revenue grows from generics demand. Biosimilars expand market share. Cost controls boost margins.
Operational improvements aid cash flow. Stable pharma needs support long growth.
Bearish Case
Competition erodes generics pricing. Negative trailing earnings signal risks. Regulatory hurdles possible.
Economic slowdowns hit healthcare spend. Margin pressures from rivals like Teva.
Market Sentiment & Investor Psychology
Short interest data limited. Institutional ownership steady.
Options show balanced calls/puts. Retail follows earnings momentum. Sentiment turns optimistic post-Q4.
Short-Term Outlook
Technicals show bullish MACD, neutral RSI. Volume up on news sustains momentum.
Expect consolidation near highs next weeks. Watch $16.47 resistance.
Medium to Long-Term Outlook
Strong generics model fits industry growth. Competitive in biosimilars.
Financial health improves with beats. Hold for dividend seekers; accumulate on dips for growth.
FAQ
Is VTRS stock a buy right now? Hold or watch; targets below current price but earnings strong.
What is the price target for VTRS stock? Average $11-12, high $15.
What are major risks for VTRS stock? Competition, pricing pressure in generics.
VTRS earnings outlook? FY EPS $2.50 expected.
Suggestions
Compare with Opendoor stock analysis.
See our generics sector valuation.
Read biosimilars forecast.
Final Balanced Conclusion
Hold VTRS stock. Earnings beats and dividends support, but analyst targets lag price. Watch for catalysts.
Disclaimer: This article is for informational purposes only and not financial advice.